NCT01208337View on ClinicalTrials.gov

Safety and Efficacy of Alemtuzumab in Pediatric Intestinal Transplantation

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions
Evidence of Liver TransplantationRejectionALEMTUZUMAB
Interventions
DRUG

Alemtuzumab

Alemtuzumab is a monoclonal antibody directed against the CD52 antigen. A single dose of 0.3-0.4 mg/kg is given to enrolled subjects at the time of intestine transplantation, 30 minutes after premedication with acetaminophen, diphenhydramine and methylprednisolone

All Listed Sponsors
lead

University of Pittsburgh

OTHER

NCT01208337 - Safety and Efficacy of Alemtuzumab in Pediatric Intestinal Transplantation | Biotech Hunter | Biotech Hunter